Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
scubamoe, regarding funds on hand, don't forget the following from the last Q:
"On July 2, 2012, we completed a public offering pursuant to which we sold 3,365,854 shares of our common stock at a price of $10.25 per share. After
deducting underwriting discounts and other estimated offering expenses payable by us, our estimated net proceeds from the transaction were $32.4 million.
We believe that our existing cash, cash equivalents and short-term investments and available capital under our committed equity line financing facility will be
sufficient to fund our anticipated operating expenses, capital expenditures and note payments for at least the next 12 months. Our assumptions include our
ability to raise capital under our $40.0 million equity line financing facility with Azimuth."
Although the lack of a partnership, or knowledge of how they will launch, could have some worried that another money raise may happen in the next few months. I would guess they need around 150 million for the 1st year of a solo launch.
That figure is what I feel they will need until the drug is bringing in revenue. they have roughly 40 million, that will get them through most of next year to approval. But you don't want a weak balance sheet. Depending on how fast the OMS302 brings in cash, they will have to raise another 60+ million, to fund 2014 and launch. So, 150 is larger side, but counting what they have now, they will need at least another 60 million.